Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial


Sezer A., KILIÇKAP S. , GÜMÜŞ M., Bondarenko I., ÖZGÜROĞLU M., Gogishvili M., ...Daha Fazla

LANCET, cilt.397, sa.10274, ss.592-604, 2021 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 397 Konu: 10274
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1016/s0140-6736(21)00228-2
  • Dergi Adı: LANCET
  • Sayfa Sayıları: ss.592-604

Özet

Background We aimed to examine cemiplimab, a programmed cell death 1 inhibitor, in the first-line treatment of advanced non-small-cell lung cancer with programmed cell death ligand 1 (PD-L1) of at least 50%.